Stay updated with breaking news from Kira Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pharmaceutical company MIRA Pharmaceuticals, Inc. (MIRA) said Tuesday it is conducting pre-clinical studies of Ketamir-2 in collaboration with Frontage Laboratories as a potential treatment for individuals battling treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and post-traumatic stress disorder (PTSD).
The Food and Drug Administration approved the first daily birth control pill in the United States that can be sold without a prescription Thursday. Approval of the progestin-only pill, called Opill by French drugmaker HRA Pharma and its parent company Perrigo, is an unprecedented move by federal regulators that advocates say should dramatically expand access to millions of women. The drug is expected to wind up on shelves at convenience stores, grocery chains and online in early 2024.
Sichuan Kelun-Biotech will partner seven preclinical antibody-drug conjugate assets with Merck in a deal that pays Kelun-Biotech $175 million upfront and up to $9.3 billion in milestones.
AIM Vaccine conducted a very small IPO on the Hong Kong exchange, raising US$20 million, which netted the company only US$10 million. The IPO saw less than 1% of the company's shares sold.
Share this article Share this article CAMBRIDGE, Mass. and SUZHOU, China, Jan. 7, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced the first closing of an oversubscribed $53.5 million Series B+ financing. The financing was co-led by RA Capital Management and Vivo Capital, with participation from Foresite Capital and APlus Partners. Existing investors, including Quan Capital and Qiming Venture Partners USA, also participated in the first closing. "While the...